HCW Biologics (NASDAQ:HCWB – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Valuation and Earnings
This table compares HCW Biologics and Roivant Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HCW Biologics | $50,000.00 | 108.19 | -$7.96 million | ($27.60) | -0.11 |
| Roivant Sciences | $8.26 million | 3,054.56 | -$299.77 million | ($0.53) | -65.91 |
Analyst Recommendations
This is a summary of current ratings and recommmendations for HCW Biologics and Roivant Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
| Roivant Sciences | 1 | 1 | 10 | 1 | 2.85 |
HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 920.41%. Roivant Sciences has a consensus target price of $35.14, suggesting a potential upside of 0.59%. Given HCW Biologics’ higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Roivant Sciences.
Profitability
This table compares HCW Biologics and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
| Roivant Sciences | -3,534.96% | -22.94% | -21.53% |
Insider and Institutional Ownership
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
HCW Biologics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Summary
Roivant Sciences beats HCW Biologics on 9 of the 15 factors compared between the two stocks.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
